Comparison
BPC-157 vs Magnesium Glycinate
Side-by-side of BPC-157 and Magnesium Glycinate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Magnesium Glycinate
Magnesium glycinate supplement guide: chelated bisglycinate form, 200 to 400 mg dosage, sleep architecture benefits, low GI side effects, glycine co-effect.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Magnesium Glycinate
- •Shortens sleep onset latency in older adults and in deficient populations supplementing 200 to 400 mg elemental Mg
- •Improves subjective sleep quality scores (PSQI, ISI) modestly versus placebo over 4 to 8 weeks
- •Reduces nocturnal leg cramps and exercise-induced muscle cramping in some controlled trials
- •Lowers self-reported anxiety in mild-to-moderate cases, with smaller effect than first-line pharmacotherapy
- •Glycinate form delivers fewer GI side effects than oxide or citrate at equivalent elemental doses
- •Insufficient as a stand-alone hypertension treatment; small adjunctive blood-pressure reductions only
Side-by-side
| Attribute | BPC-157 | Magnesium Glycinate |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | magnesium bisglycinate |
| Half-life (hr) ↗ | 4 | 5 |
| Typical dose (mg) ↗ | 0.25 | 300 |
| Dosing frequency | daily (anecdotal protocols) | daily (often evening) |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 1 |
| Molecular formula | C62H98N16O22 | - |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Magnesium acts as a cofactor for 300+ enzymes and as a voltage-dependent antagonist at NMDA receptors; glycine serves as an inhibitory neurotransmitter and co-agonist at glycine receptors. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement |
| Pregnancy | Insufficient data | Generally considered acceptable at RDA doses; consult clinician |
| CAS | 137525-51-0 | 14783-68-7 |
| PubChem CID | 9941957 | 84645 |
| Wikidata | Q4835418 | - |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Magnesium Glycinate
Common side effects
- mild GI upset at high doses
- loose stools (dose-dependent, less than with oxide/citrate forms)
Contraindications
- severe renal impairment
- myasthenia gravis
- heart block
Interactions
- tetracycline and fluoroquinolone antibiotics: magnesium chelates antibiotic, reducing absorption; separate by 2+ hours(moderate)
- bisphosphonates: reduced absorption of bisphosphonate(moderate)
- potassium-sparing diuretics: possible hypermagnesemia in renal impairment(moderate)
Which Should You Take?
Magnesium Glycinate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is sleep onset or sleep quality, pick Magnesium Glycinate.
- → If your priority is stress and HPA-axis regulation, pick Magnesium Glycinate.
Edge case: If you want to avoid research-only / gray-market sourcing, Magnesium Glycinate is the more accessible choice.
Default choice: Magnesium Glycinate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Magnesium Glycinate?
BPC-157 and Magnesium Glycinate differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Magnesium Glycinate?
BPC-157 half-life is 4 hours; Magnesium Glycinate half-life is 5 hours.
Can you stack BPC-157 with Magnesium Glycinate?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper